School of kinesiology, Shanghai University of sport, No. 200 Hengren Road, Yangpu District, Shanghai, 200438, China.
Department of Rehabilitation Medicine, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, Shanghai, 201318, China.
J Mol Neurosci. 2020 Aug;70(8):1244-1254. doi: 10.1007/s12031-020-01533-8. Epub 2020 Mar 26.
Post-stroke cognitive impairment (PSCI), as one of the major complications after stroke, refers to a series of syndromes from mild cognitive impairment to dementia caused by stroke. Stroke has been reported to increase the risk of cognitive impairment by at least five to eight times. The assessment of PSCI usually relies on neuropsychological tests, but the results of these tests are subjective and inaccurate, and can be insufficient for the diagnosis and prognosis of PSCI. In recent years, an increasing number studies have indicated that changes in the expression of biomarkers such as C-reactive protein (CRP), interleukin 6 (IL-6) and IL-10 in blood, urine and other body fluids are associated with cognitive decline after stroke. Therefore, the detection of biomarkers in circulating blood serum, plasma and cerebrospinal fluid (CSF) may improve the accuracy of diagnosis and prognosis in PSCI. This review aims to summarize the studies on potential molecular biomarkers of PSCI.
脑卒中后认知障碍（PSCI）是脑卒中后的主要并发症之一，是指由脑卒中引起的一系列从轻度认知障碍到痴呆的综合征。据报道，脑卒中使认知障碍的风险至少增加了五到八倍。PSCI 的评估通常依赖于神经心理学测试，但这些测试的结果是主观的，不准确的，并且可能不足以诊断和预测 PSCI。近年来，越来越多的研究表明，血液、尿液和其他体液中 C 反应蛋白（CRP）、白细胞介素 6（IL-6）和白细胞介素 10 等生物标志物的表达变化与脑卒中后认知能力下降有关。因此，检测循环血清、血浆和脑脊液（CSF）中的生物标志物可能会提高 PSCI 的诊断和预后准确性。本综述旨在总结 PSCI 的潜在分子生物标志物的研究进展。
